Emiliano Calvo

Emiliano Calvo

UNVERIFIED PROFILE

Are you Emiliano Calvo?   Register this Author

Register author
Emiliano Calvo

Emiliano Calvo

Publications by authors named "Emiliano Calvo"

Are you Emiliano Calvo?   Register this Author

80Publications

2154Reads

47Profile Views

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

J Clin Pharmacol 2019 Aug 15;59(8):1099-1109. Epub 2019 Mar 15.

QCP, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1403DOI Listing
August 2019

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Eur J Cancer 2018 11 1;104:1-8. Epub 2018 Oct 1.

Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.07.011DOI Listing
November 2018

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

J Clin Oncol 2018 10 15;36(28):2836-2844. Epub 2018 Aug 15.

Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834PMC
October 2018

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors.

Mol Cancer Ther 2018 01;17(1):3-16

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Division, Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0349DOI Listing
January 2018

Immunotherapy-based combinations: current status and perspectives.

Curr Opin Oncol 2017 Sep;29(5):382-394

aSTART Madrid-Centro Integral Oncológico Clara Campal, Sanchinarro University Hospital, Madrid, Spain bCentro Hospitalar Lisboa Norte EPE, Hospital de Santa Maria, Oncology Department, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000391DOI Listing
September 2017

The future of oncology therapeutics.

Expert Rev Anticancer Ther 2017 07 22;17(7):563-565. Epub 2017 May 22.

b START Madrid , Oncology Phase I Unit, Centro Integral Oncológico Clara Campal , Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1331131DOI Listing
July 2017

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.

BMC Cancer 2017 02 15;17(1):137. Epub 2017 Feb 15.

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Division, Hospital Universitario Madrid Norte Sanchinarro, Calle Oña, 10, 28050, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3131-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312529PMC
February 2017

Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.

Am Soc Clin Oncol Educ Book 2016 ;35:e175-84

From the DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center, Tampa, FL; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Platform of Oncology, Hospital Quirón, Torrevieja, Alicante, Spain; START Madrid, Early Clinical Drug Development Program, Centro Integral Oncológico Clara Campal, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159061DOI Listing
January 2017

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.

Oncology 2016 7;91(5):251-260. Epub 2016 Sep 7.

START Madrid, Centro Integral Oncológico Clara Campal, Madrid Norte Sanchinarro University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000448621DOI Listing
January 2017

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Cancer Treat Rev 2016 Nov 10;50:109-117. Epub 2016 Sep 10.

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.09.002DOI Listing
November 2016

Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.

Invest New Drugs 2016 Apr 14;34(2):193-201. Epub 2016 Jan 14.

Research and Development Department, Spectrum Pharmaceuticals, 157 Technology Drive, Irvine, CA, 92618, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0321-8DOI Listing
April 2016

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

J Clin Oncol 2015 Oct 31;33(30):3401-8. Epub 2015 Aug 31.

Josep Tabernero, Rodrigo Dienstmann, Barbara Adamo, and Jordi Rodon, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal; Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain; Rastislav Bahleda, Anas Gazzah, and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif; Antoine Italiano, Institut Bergonié, Bordeaux, France; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Bob Zhong, Suso J. Platero, Moitreyee Chatterjee-Kishore, Vijay Peddareddigari, and Feng R. Luo, Janssen Research and Development, Raritan, NJ; and Johan W. Smit and Kim Stuyckens, Janssen Research and Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7341DOI Listing
October 2015

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.

Target Oncol 2015 Mar 15;10(1):111-23. Epub 2014 Jun 15.

Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11523-014-0320-2
Publisher Site
http://dx.doi.org/10.1007/s11523-014-0320-2DOI Listing
March 2015

New approach to cancer therapy based on a molecularly defined cancer classification.

CA Cancer J Clin 2014 Jan-Feb;64(1):70-4. Epub 2013 Nov 18.

Head of the Breast Cancer and Melanoma Programs, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Medical Oncologist, Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21211DOI Listing
March 2014

What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?

Cancer Treat Rev 2013 Jun 23;39(4):366-74. Epub 2012 Jul 23.

Centro Integral Oncológico Clara Campal and START Madrid, Madrid, Spain.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372120014
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2012.06.010DOI Listing
June 2013

Simultaneous online SPE-HPLC-MS/MS analysis of docetaxel, temsirolimus and sirolimus in whole blood and human plasma.

J Chromatogr B Analyt Technol Biomed Life Sci 2013 Mar 28;921-922:35-42. Epub 2013 Jan 28.

CEMBIO (Center for Metabolomics and Bioanalysis), Facultad de Farmacia, Universidad CEU San Pablo, Campus Montepríncipe, Boadilla del Monte, 28668 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2013.01.017DOI Listing
March 2013

Reply to A. Ocana et al.

J Clin Oncol 2013 Mar;31(9):1253-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.8271DOI Listing
March 2013

Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.

Anticancer Res 2012 Jul;32(7):2399-406

Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

View Article

Download full-text PDF

Source
July 2012

Non-clear cell advanced kidney cancer: is there a gold standard?

Anticancer Drugs 2011 Jan;22 Suppl 1:S9-14

Centro Integral Oncológico Clara Campal, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cad.0000390767.85658.83DOI Listing
January 2011

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.

Am J Respir Crit Care Med 2010 Aug 1;182(3):396-403. Epub 2010 Mar 1.

Memorial Sloan-Kettering Cancer Center, Pulmonary Medicine, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.200911-1720OCDOI Listing
August 2010

Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.

Clin Cancer Res 2009 Jun 19;15(11):3866-71. Epub 2009 May 19.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2373DOI Listing
June 2009

Multiple roles and therapeutic implications of Akt signaling in cancer.

Onco Targets Ther 2009 Feb 18;2:135-50. Epub 2009 Feb 18.

Centro Integral Oncológico Clara Campal (CIOCC), Madrid. Spain;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886325PMC
February 2009

Acute severe hypothyroidism induced by sunitinib.

Radiother Oncol 2008 Oct 24;89(1):124-5. Epub 2008 May 24.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2008.05.007DOI Listing
October 2008

Novel agents that target tublin and related elements.

Semin Oncol 2006 Aug;33(4):421-35

ImClone Systems Inc, Branchburg, NJ 08876, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2006.04.006DOI Listing
August 2006

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.

J Clin Oncol 2006 May;24(14):2158-63

Vall d'Hebron University Hospital, Universidad Autónoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.06.5961DOI Listing
May 2006

Clinical experience with monoclonal antibodies to epidermal growth factor receptor.

Curr Oncol Rep 2005 Mar;7(2):96-103

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, 4th Floor, Zeller Building, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
March 2005

Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor.

Curr Oncol Rep 2005 Mar;7(2):123-8

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, 4th Floor, Zeller Building, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
March 2005

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.

Clin Lung Cancer 2004 Dec;6 Suppl 1:S35-42

Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
December 2004

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.

Clin Cancer Res 2004 Nov;10(21):7112-20

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1187DOI Listing
November 2004

Hepatic artery chemotherapy and colorectal liver mestastases.

Lancet 2003 May;361(9370):1743; author reply 1743

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0140-6736(03)13342-9DOI Listing
May 2003

Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study.

Breast Cancer Res Treat 2002 Nov;76(1):47-56

Department of Oncology, Clínica Universitaria de Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1020273502426DOI Listing
November 2002

Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.

Authors:
Emiliano Calvo

Clin Colorectal Cancer 2002 Nov;2(3):170-2

Oncology Dept, Hospital San Jaime, Alicante, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1533-0028(11)70323-1DOI Listing
November 2002